本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
DHAKA, Bangladesh, Jan. 3, 2025 /PRNewswire/ -- On December 24, 2024, the Padma Bridge Rail Link Project (PBRLP) in Bangladesh officially opened across its entire line to traffic. CASCO, one of the key Chinese participating enterprises, was invited to attend the opening ceremony. The PBRLP stretches approximately 168 km with 20 stations. It is the largest railway project under the Belt and Road initiative between China and Bangladesh, and is also the largest infrastructure project in Bangladesh's history in terms of scale and investment. Following its opening, it will directly benefit a population of 80 million and drive Bangladesh's economic growth by 1.5%, making it the "Dream Road" for the locals. As the EPC integrator of telecommunication and signaling systems for the railway, CASCO undertook the telecommunication and signaling project, including engineering design, proposal design, equipment procurement, transportation, installation, construction, testing, commissioning, quality assurance and subsequent maintenance support. This is the first time that Chinese telecommunication and signaling solutions have been applied in Bangladesh railway, marking a significant breakthrough for Chinese standards and technology in international markets. Despite challenges such as insufficient preconditions, toilsome and difficult construction tasks, the CASCO project team systematically coordinated resource allocation, continually refined construction plans, and proactively overcame obstacles. These efforts ensured that the project progressed smoothly and opened with high quality, thereby showcasing exceptional management of large-scale projects. The team received high praise from the Bangladeshi client, supervisor, and general contractor for the service, technical solutions, construction processes, and equipment performance that were provided. This gives CASCO a stellar reputation within the market. With the railway linking up the north and south, the once insurmountable moat has now become a main thoroughfare. The trains speeding across the Padma River has not only turned the dreams of the Bangladeshis into a reality, but also highlighted CASCO's positive contribution to advancing the Belt and Road construction. As a leading enterprise in China's rail transit sector, CASCO will continue to uphold the principles of open cooperation and mutual benefits, and contribute Chinese wisdom and technological strength to global rail transit development.
SINGAPORE - Media OutReach Newswire - 3 January 2025 - Flint, the pioneering deep tech company developing a proprietary paper battery technology, has raised US$2 million in seed funding. This funding round, led by a global consortium of angel investors, will accelerate Flint’s efforts to bring high-performance, sustainable energy storage solutions to market. “This funding milestone represents years of technical breakthroughs, and now, with real-world applications on the horizon, we are laser-focused on delivering our solutions to market,” said Mr. Carlo Charles, Founder and CEO of Flint, who has been recognized by the US State Department, the European Union, Google, TechCrunch, the International Union for Conservation of Nature, the Singapore government, and other esteemed institutions. “Our batteries are engineered to excel where traditional technologies fall short, and we believe they will transform industries that demand superior safety, sustainability, and flexibility.” The funding supports commercial expansion, pilot production, and intellectual property development, positioning Flint to challenge legacy battery technologies like lithium-ion and lead-acid with cleaner, safer, and adaptive alternatives. The company is also set to roll out its first paid pilot project in the immediate future with an international customer in a diversified industry sector. Key Highlights: US$2 million seed funding raised from private investors across nine countries and AI-driven VC firm Hatcher+. First commercial pilot project secured with a global enterprise, validating Flint’s market readiness. Stealth mode exit after intensive R&D and proprietary battery designs now ready for commercialization. Funds allocated toward pilot production, key hires, and intellectual property development. Deep Tech Innovation: Rethinking Energy Storage Flint’s cellulose-based paper batteries are engineered from the ground up to solve critical challenges in modern energy storage. These next-generation batteries are: Highly Sustainable: Using natural and non-toxic materials such as cellulose paper, zinc and manganese, Flint eliminates hazardous components used in conventional battery technologies and are fully compostable at the end of their lifecycle, making recycling easier and cheaper, minimizing electronic wastes, and reducing environmental impact. Inherently Safe: Explosion-proof, leak-proof, and immune to combustion risks, ensuring near-zero fire hazards even under extreme conditions. Flexible and Durable: Flexible and designed to maintain functionality even when punctured, bent, or damaged, allowing new form factors for various applications. Cost-Efficient: Leveraging low-cost input materials and scalable production processes, Flint addresses pricing concerns that have traditionally hindered the adoption of sustainable technologies. Scalable for Rapid Adoption: Seamlessly integrates into existing manufacturing infrastructure, lowering barriers to industrial adoption and allowing for quick scaling. These innovations represent a fundamental shift in energy storage, laying the groundwork for smarter, safer, and more environmentally sustainable batteries. Flint’s core technology addresses both anode and cathode breakthroughs, with proprietary electrolytes and separators enhancing performance, stability, and safety under extreme conditions. Furthermore, Flint’s proprietary innovations not only address sustainability challenges but also remove the traditional “green premium” — the higher cost often associated with environmentally friendly products. For standard battery types and applications, Flint’s inexpensive input materials and efficient production processes enable competitively priced solutions. These solutions not only match the performance of conventional batteries but also provide a “green discount”: a more sustainable product at a lower price. Strong Market Traction with High-Value Customers With a global energy storage market valued at US$500 billion by 2030, Flint is strategically positioned to disrupt the industry. The company’s first paid pilot project with a diversified international enterprise validates its value proposition and underscores early market traction. Flint has already attracted interest from more than 20 companies across sectors, including: Defense and Security Energy Storage Systems Critical Power Supply Consumer Electronics Space Applications Electric Vehicles (EVs) "These discussions highlight a growing appetite for next-generation energy solutions," said Mr. Carlo Charles. “Our cost-effectiveness is key to driving adoption at scale. We’re not just offering a sustainable option; we’re offering a better, safer, and more affordable alternative to unsustainable batteries.” “A lower production cost is at the core of creating demand, scaling quickly, and increasing adoption rates while ensuring profitability,” said Mr. Jeremy Wee, Co-Founder of Flint. “We are no longer confined to the lab — our commercial pilots are already demonstrating the tangible impact of our innovations in real-world applications.” Investor Confidence and Funding Roadmap The US$2 million seed funding round which closed in October was driven by private angel investors from France, Germany, Hong Kong, India, Singapore, Sweden, Switzerland, the UK, and the US. It also saw participation from Hatcher+, a venture capital firm recognized for leveraging machine learning and AI-driven insights to identify high-potential ventures. The capital infusion will be deployed to: Scale pilot production capabilities Secure intellectual properties to safeguard proprietary technologies Build a world-class team of engineers and scientists Drive commercialization efforts with pilot customers “This announcement marks a major milestone for us as a company, and we are very humbled by the support from our investors, who, like us, believe in a better and greener future,” said Mr. Carlo Charles. This funding builds on Flint’s national and international recognition from TechCrunch, the Techblazer Awards, the Institution of Engineers Singapore (IES), and accelerator programs by Shell and OPPO, along with grants from the Singapore government — further validating the company’s breakthrough potential. Upcoming CES 2025 Global Launch Flint will also showcase its prototypes and products at CES 2025 in Las Vegas from January 7th–10th, presenting to global tech leaders and strategic partners. CES is labelled the most powerful tech event in the world with more than 130,000 attendees expected. At the end of 2023, Flint made its debut on the global stage of TechCrunch’s flagship event in San Francisco, standing out as the only company from Asia among just 20 start-ups selected worldwide out of a total of more than 3,200. Building on that momentum, Flint is now ready to leverage CES 2025 as a strategic launchpad for accelerated international expansion. Shaping the Future of Sustainable Technology “At Flint, we aim to do more than build better batteries — we’re changing the way the world envisions energy storage,” said Carlo Charles. “By positioning ourselves at the intersection of advanced technology and sustainability, we’re addressing the climate crisis head-on. Our paper battery technology isn’t just about better performance; it’s about creating a safer, greener standard that industries can rely on. This is the future of energy, and we’re proud to be leading the way.” Our goal is simple: to create batteries that work great and are better for the planet,” added Mr. Jeremy Wee. “We’re not just solving today’s problems — we’re preparing for tomorrow and setting new standards for what’s possible in sustainability.” Hashtag: #Flint #FlintPaperBattery #GreenEnergy #DeepTech #SustainableInnovation #CleanTech #FutureOfEnergy #PaperBattery #EnergyStorage #StartupFunding #SeedFunding #TechInvestment #GlobalInnovation #ClimateTech #CES2025 #TechCrunchDisrupt #MadeByFlint #TechLeadershttps://www.madebyflint.co/https://www.linkedin.com/company/madebyflint/The issuer is solely responsible for the content of this announcement.FlintSparkByFlint Pte. Ltd. ("Flint") is a deep tech impact company headquartered in Singapore with a mission to offer the world’s most sustainable batteries. Flint specializes in developing next-generation rechargeable paper batteries that are safer, cleaner, and more flexible and cost-efficient than traditional lithium-ion and lead-acid batteries. Flint’s proprietary technology encompasses anode, cathode, separator, and electrolyte innovations, with cellulose paper at its core. The company’s batteries remain operational even when damaged and integrate easily with existing manufacturing processes, enabling rapid industrial adoption. For more information, visit www.madebyflint.co.
SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The approval is based on positive results from the pivotal Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated the safety, tolerability and efficiency of taletrectinib in Chinese patients with advanced ROS1-positive NSCLC. The findings, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology (JCO), demonstrated that taletrectinib continued to show high and durable overall responses and robust activity against intracranial lesions. In ROS1 TKI-naïve (n=106) patients, confirmed objective response rate (cORR, as assessed by an independent review committee, IRC) and intracranial cORR reached as high as 91% and 88%, respectively. After median follow-up of 23.5 months in TKI-naïve patients, median duration of response (IRC-assessed) and median progression-free survival (IRC-assessed) were not reached. [Link] In December 2024, DOVBLERON® was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. DOVBLERON® is the 13th addition to Innovent's commercial portfolio, representing an innovative precision therapy expected to benefit more lung cancer patients alongside our strong TKI franchise. Caicun Zhou, M.D., Ph.D., Director of the Department of Oncology at Shanghai East Hospital, Tongji University, commented: "We are glad to see that DOVBLERON® has been approved for ROS1-positive NSCLC across treatment lines at a fast pace. DOVBLERON® demonstrated superior efficacy compared to the first-generation TKIs. These TRUST-I results reinforce taletrectinib's high overall response and prolonged PFS. The efficacy and safety profile of DOVBLERON® offers a more effective first-line treatment option and I look forward to its benefit in the ROS1-positive NSCLC patients in China." Dr. Hui Zhou, Senior Vice President of Innovent, stated: "The two NDAs approval of DOVBLERON® is a reflection of its potential best-in-class efficacy to fulfill the urgent need of patients with ROS1-positive NSCLC. We recently just launched the first batch of DOVBLERON® to market, rapidly bringing this precision therapy to NSCLC patients who need novel treatment options. Innovent's robust TKI product pipeline—including RETSEMOV®, PEMAZYRE®, DUPERT® and DOVBLERON®—showcases our leadership and synergistic strengths in precision oncology. We endeavor to advance more innovative medicines to enhance patients' quality of life." About ROS1-positive Non-small Cell Lung Cancer Lung cancer continues to have one of the highest global incidences and mortality rates, with NSCLC accounting for about 85% of all cases. In China, it is estimated that approximately 2.6% of patients living with NSCLC are ROS1-positive[i]. Despite recent progress for patients with ROS1-positive NSCLC, there remains a need for more effective and tolerable treatment options. In patients with metastatic ROS1-positive NSCLC that progressed following initial treatment, many have tumors spread to their brain (up to 55%) or acquired resistance mutations, including G2032R. Next-generation ROS1 TKIs demonstrated robust intracranial and G2032R activity. In the clinical management of ROS1-positive NSCLC patients, the first-line application of the new generation ROS1 TKIs can bring a prolonged progression-free survival and provide patients with greater survival benefits. About DOVBLERON ® (Taletrectinib Adipate Capsule) DOVBLERON® is an oral, potent, central nervous system-active, selective, next-generation ROS1inhibitor. Taletrectinib, the active ingredient in DOVBLERON® is being evaluated for the treatment of patients with advanced ROS1-positive NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study. DOVBLERON® was approved by China's National Medical Products Administration (NMPA): 1) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who have previously been treated with ROS1 TKIs; 2) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. Taletrectinib has been granted Orphan Drug Designation by the U.S. FDA for the treatment of patients with ROS1-positive NSCLC and other NSCLC indications, and Breakthrough Therapy Designations by both the U.S. FDA and China's NMPA for the treatment of patients with locally advanced or metastatic ROS1-positive NSCLC. Based on pooled results of the TRUST-I and TRUST-II clinical studies, Nuvation Bio Inc. (NYSE: NUVB) submitted an NDA for taletrectinib to the U.S. FDA for the treatment of patients with advanced ROS1-positive NSCLC (line agnostic, full approval). This NDA was accepted by the U.S. FDA for priority review in December 2024. In June 2021, Innovent and AnHeart Therapeutics (Hangzhou) Co. Ltd., a Nuvation Bio Inc. company, entered into an exclusive license agreement for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau and Taiwan. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. References [i] Zhang et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer. 2019 Jan;10(1):47-53.
Lending revenue dips against backdrop of record-high indices NEW YORK, Jan. 3, 2025 /PRNewswire/ -- The global securities finance industry generated $9.64 billion in revenue for lenders in 2024, according to DataLend, the market data service of fintech EquiLend. The figure represents a 10.3% decrease from the $10.74 billion generated in 2023. Global broker-to-broker activity, where broker-dealers lend and borrow securities from each other, totaled an additional $2.57 billion in revenue for 2024, a 9.9% decrease from 2023. Equity lending revenues fell 13% globally, with North America revenue declining 15% and EMEA revenue dropping 24%. In North America, the cause for the revenue decline was a 19% decrease in average fees, while in EMEA, fees and balances decreased 16% and 11%, respectively. Equity lending revenues in APAC were largely flat year-over-year. Global sovereign debt revenue increased by 8% over 2023, with U.S. treasuries making up the lion's share of the gains. Treasuries were up 16% year-over-year, driven by a 14% growth in balances. In corporate debt lending, global revenue declined by 21% as a regression from a record 2023 continued. Fees were the main culprit, with a steep 29% decrease driving the year-over-year decline in revenue. The top five earning securities in 2024 were Sirius XM Holdings (SIRI US), Lucid Group (LCID US), Beyond Meat Inc. (BYND US), Tempus AI Inc. (TEM US) and Trump Media & Technology Group (DJT US). The five securities in total generated $644 million for lenders over the course of 2024, a significant dip from the $1.11 billion generated by 2023's top five earners. Bloomberg Terminal users can subscribe to EquiLend's exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA <GO> or clicking the following link: https://blinks.bloomberg.com/screens/apps%20orbisa. About DataLendDataLend, the market data service within EquiLend's Data & Analytics Solutions group, tracks daily market movements across more than 200,000 securities, covering $35 trillion in lendable assets and $2.6 trillion in on-loan assets for the securities finance market. www.datalend.com About EquiLendEquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. EquiLend has offices in North America, EMEA and Asia-Pacific and is regulated in jurisdictions around the globe. www.equilend.com
資深科技高管加入DXC領導團隊 維珍尼亞州阿什伯恩2025年1月3日 /美通社/ -- 《財富》雜誌500強領先全球科技服務供應商DXC Technology（紐約證券交易所代碼：DXC）今日宣佈委任Brad Novak為資訊總監。Novak加入DXC領導團隊，並專注於在DXC業務營運中全面應用人工智能（AI）技術。他將向DXC行政總監James Walker匯報。 Brad Novak, Chief Information Officer, DXC Technology 在此職位上，Novak將策略性地在基礎設施中嵌入人工智能（AI）技術。他還將領導團隊整合、標準化及統一各種平台、工具和流程，以提升員工生產力和營運效率。 Novak是一位資深科技專家，擁有超過30年金融服務領域的經驗，涵蓋應用程式開發、基礎設施以及服務管理。他曾在多家全球金融服務機構工作，最近在巴克萊銀行（Barclays）擔任企業及投資銀行（Corporate and Investment Bank）的技術總監，負責領導技術架構和策略。Novak亦曾在私募股權和風險投資領域工作，評估投資機會並為投資組合公司提供技術策略建議。 欲了解有關DXC領導團隊的詳細資訊，請按此處。 前瞻性陳述 本新聞稿中，全部與歷史事實不直接兼完全相關的陳述，均構成「前瞻性陳述」。這些陳述代表目前期望和信念，並不保證任何前瞻性陳述所列的任何結果、目標或計劃均可或將會實現。此類陳述受眾多假設、風險、不確定和其他因素所影響。這些因素可能導致實際結果與此類陳述中描述的結果，存在重大差異。當中許多因素，超出我們的控制範圍。欲了解這些因素的書面描述，請參閱DXC的表格10-K（財政年度截至2024年3月31日的年報）的「風險因素」標題部份，以及後續向SEC申報的任何更新資料。讀者切勿過度依賴此類陳述，而此類陳述僅限聲明當日為準。除非法律要求，我們不承擔任何更新義務、為任何前瞻性陳述發佈任何修訂、本文件日期之後報告任何事件或情況或反映發生意外事件。 DXC Technology簡介 DXC Technology（紐約證券交易所代碼：DXC）協助世界各地的企業執行他們的重要任務系統和營運操作、實現資訊科技（IT）現代化、儘量提升資料架構，並確保跨公共雲端、私人雲端和混合型雲端的安全和可擴展。全球多間大型企業和公營部門組織信任DXC作各項服務部署，從而提升自身的資訊科技（IT）資產表現、競爭力和客戶體驗至新一層樓。請瀏覽DXC.com，進一步了解我們如何在為客戶和同事提供卓越服務。 聯絡方法：Mihir Bellamkonda，媒體關係，mihir.bellamkonda@dxc.com；Roger Sachs，投資者關係，roger.sachs@dxc.com
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care. The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment. In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed." CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed." Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems. ABOUT CATHWORKS CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn. Investors:Mike Fehermike.feher@cath.works Media:Sarita Monicosarita.monico@cath.works
A12 藝術空間
D-Link
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
